drugset / Trial / NCT01012284
A Study of TMC207 in Patients With Moderately Impaired Hepatic Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the pharmacokinetics (what the body does to the medication), safety and tolerability of TMC207 and its N-monodesmethyl metabolite (M2) in healthy participants and in patients with moderate hepatic impairment after administration of a single 400 mg dose of TMC207.
Timeline
- Start
- 2010-01
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bedaquiline | Small molecule | 400 mg | — |
Indications
No indication recorded.